Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity

J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allergens / immunology*
  • Animals
  • Antigen-Presenting Cells / immunology*
  • Antigens, Plant / immunology*
  • CHO Cells
  • Cricetulus
  • Desensitization, Immunologic*
  • Escherichia coli / genetics
  • Female
  • Genetic Engineering
  • Glycosylation
  • Humans
  • Mice, Inbred BALB C
  • Pichia / genetics
  • T-Lymphocytes / immunology*
  • Vaccines*

Substances

  • Allergens
  • Antigens, Plant
  • Vaccines
  • Bet v 1 allergen, Betula